BMC Medicine,
Journal Year:
2023,
Volume and Issue:
21(1)
Published: Nov. 20, 2023
Leveraging
a
large
nationwide
study
of
Icelandic
women,
we
aimed
to
narrow
the
evidence
gap
around
female
attention-deficit/hyperactivity
disorder
(ADHD)
and
cardiometabolic
comorbidities
by
determining
prevalence
obesity,
hypertension,
type
2
diabetes,
cardiovascular
diseases
among
women
with
ADHD
examine
association
between
conditions
co-occurring
anxiety
mood
disorders,
alcoholism/substance
use
(SUD),
self-harm,
suicide
attempts.
JAMA,
Journal Year:
2024,
Volume and Issue:
331(10), P. 850 - 850
Published: March 12, 2024
Importance
Attention-deficit/hyperactivity
disorder
(ADHD)
is
associated
with
increased
risks
of
adverse
health
outcomes
including
premature
death,
but
it
unclear
whether
ADHD
pharmacotherapy
influences
the
mortality
risk.
Objective
To
investigate
initiation
was
reduced
risk
in
individuals
ADHD.
Design,
Setting,
and
Participants
In
an
observational
nationwide
cohort
study
Sweden
applying
target
trial
emulation
framework,
we
identified
aged
6
through
64
years
incident
diagnosis
from
2007
2018
no
medication
dispensation
prior
to
diagnosis.
Follow-up
started
until
emigration,
2
after
diagnosis,
or
December
31,
2020,
whichever
came
first.
Exposures
defined
as
dispensing
within
3
months
Main
Outcomes
Measures
We
assessed
all-cause
well
natural-cause
(eg,
physical
conditions)
unnatural-cause
unintentional
injuries,
suicide,
accidental
poisonings).
Results
Of
148
578
(61
356
females
[41.3%]),
84
204
(56.7%)
initiated
medication.
The
median
age
at
17.4
(IQR,
11.6-29.1
years).
2-year
lower
treatment
strategy
group
(39.1
per
10
000
individuals)
than
noninitiation
(48.1
individuals),
a
difference
−8.9
(95%
CI,
−17.3
−0.6).
significantly
rate
(hazard
ratio
[HR],
0.79;
95%
0.70
0.88)
(2-year
risk,
25.9
vs
33.3
individuals;
difference,
−7.4
−14.2
−0.5;
HR,
0.75;
0.66
0.86),
not
13.1
14.7
−1.6
−6.4
3.2;
0.86;
0.71
1.05).
Conclusions
Relevance
Among
diagnosed
ADHD,
mortality,
particularly
for
death
due
unnatural
causes.
JCPP Advances,
Journal Year:
2023,
Volume and Issue:
3(3)
Published: April 5, 2023
Abstract
Attention‐deficit/hyperactivity
disorder
(ADHD)
often
co‐occurs
with
other
psychiatric
and
physical
diseases.
However,
available
evidence
on
associations
between
ADHD
cardiovascular
diseases
(CVDs)
is
mixed.
To
systematically
review,
quantitatively
synthesize,
appraise
the
link
CVDs,
we
searched
relevant
articles
in
PubMed,
Embase,
PsycINFO,
Web
of
Science
from
inception
to
May
1,
2022.
Study
quality
was
assessed
by
using
Newcastle‐Ottawa
Scale,
random‐effects
model
meta‐analyses
were
performed.
A
total
18,391,169
(ADHD:
n
=
421,224)
individuals
11
studies
included
our
systematic
review
8,196,648
(ADHD
332,619)
five
main
meta‐analysis
adjusted
estimates.
Pooled
estimates
showed
that
significantly
associated
an
increased
risk
CVDs
analyses
based
effect
size
(odds
ratio
(OR)
1.96;
95%
confidence
interval
(CI)
1.19–2.23,
Q
140.74,
P
<
0.001,
I
2
97.2%).
When
restricted
among
adults,
heterogeneity
declined
null
(OR
1.73;
CI
1.14–2.62,
6.28,
0.10,
6.28%),
suggesting
age
might
be
source
heterogeneity.
In
subgroup
analyses,
found
across
groups,
type
data
sources.
This
indicate
for
but
further
various
study
designs
are
warranted
advance
understanding
underlying
mechanisms
observed
association
CVDs.
Additional
research
also
needed
resolve
role
medications
which
remains
unclear
due
limited
number
primary
exploring
this
issue.
JAMA Network Open,
Journal Year:
2024,
Volume and Issue:
7(3), P. e241349 - e241349
Published: March 6, 2024
Importance
There
are
concerns
about
the
safety
of
medications
for
treatment
attention-deficit/hyperactivity
disorder
(ADHD),
with
mixed
evidence
on
possible
cardiovascular
risk.
Objective
To
assess
whether
short-term
methylphenidate
use
is
associated
risk
events.
Design,
Setting,
and
Participants
This
retrospective,
population-based
cohort
study
was
based
national
Swedish
registry
data.
were
individuals
ADHD
aged
12
to
60
years
dispensed
prescriptions
between
January
1,
2007,
June
30,
2012.
Each
person
receiving
(n
=
26
710)
matched
birth
date,
sex,
county
up
10
nonusers
without
225
672).
Statistical
analyses
performed
from
September
13,
2022,
May
16,
2023.
Main
Outcomes
Measures
Rates
events,
including
ischemic
heart
disease,
venous
thromboembolism,
failure,
or
tachyarrhythmias,
1
year
before
6
months
after
initiation
compared
controls
using
a
bayesian
within-individual
design.
Analyses
stratified
by
history
Results
The
included
252
382
(15
442
[57.8%
men];
median
age,
20
(IQR,
15-31)
years).
overall
incidence
events
1.51
per
000
person-weeks
(95%
highest
density
interval
[HDI],
1.35-1.69)
0.77
HDI,
0.73-0.82)
controls.
Individuals
treated
had
an
87%
posterior
probability
having
higher
rate
(incidence
ratio
[IRR],
1.41;
95%
1.09-1.88)
(IRR,
1.18;
1.02-1.37).
probabilities
70%
at
least
10%
increased
in
vs
49%
No
difference
found
this
disease
1.11;
0.58-2.13).
Conclusions
Relevance
In
study,
small
initiation.
However,
there
little
20%
differences
increase
people
disease.
Therefore,
initiation,
careful
consideration
risk-benefit
trade-off
would
be
useful,
regardless
history.
Expert Review of Gastroenterology & Hepatology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 15, 2025
Introduction
Metabolic
dysfunction-associated
steatotic
liver
disease
(MASLD)
is
increasingly
becoming
more
prevalent
in
the
general
population.
MASLD
common
persons
with
low
socioeconomic
status
(SES),
yet
little
known
about
psychosocial
challenges
associated
this
disease,
and
clinical
recommendations
on
how
to
approach
are
lacking.
Acta Psychiatrica Scandinavica,
Journal Year:
2024,
Volume and Issue:
150(2), P. 105 - 117
Published: May 28, 2024
Abstract
Objective
A
thorough
and
comprehensive
knowledge
base
on
the
extent
of
comorbidity
attention‐deficit/hyperactivity
disorder
(ADHD)
somatic
conditions
is
needed.
Method
We
compared
prevalence
a
wide
range
in
individuals
with
without
ADHD
described
sex
lifecourse
differences.
Individuals
an
diagnosis
(
N
=
87,394)
age
sex‐matched
were
identified
from
large
health
claims
dataset
representative
general
German
population,
including
both
primary
specialized
care
4.874,754).
Results
provided
for
full
sample
as
well
stratified
(<12
years,
13–17
18–29
30–59
≥60
years).
The
results
showed
that
associated
variety
across
entire
lifecourse.
Specifically
neurological
disorders
such
Parkison's
disease
(odds
ratio
[OR]:
5.21)
dementia
(OR:
2.23),
sleep‐related
2.38)
autoimmune
affecting
musculoskeletal,
digestive,
endocrine
system
(fibromyalgia
OR:
3.33;
lupus
2.17)
are
strongly
significantly
ADHD.
Additionally,
higher
occurrence
common
acute
diseases
typically
treated
by
practitioner,
hinting
at
overall
lower
status.
Sex
differences
not
prominent.
Age
differences,
contrast,
stood
out:
particular
endocrine,
cardiovascular,
had
early
onset
to
Conclusion
This
research
underlines
high
burden
due
among
findings
indicate
need
preventive
measures
reduce
comorbidity.
Vertex Revista Argentina de Psiquiatría,
Journal Year:
2025,
Volume and Issue:
35(166), P. 56 - 84
Published: Jan. 10, 2025
El
trastorno
por
déficit
de
atención
e
hiperactividad
(TDAH)
ha
sido
tradicionalmente
concebido
como
una
condición
privativa
la
infancia.
Sin
embargo,
creciente
evidencia
sugiere
que
el
TDAH
persiste
en
vida
adulta,
manifestándose
diversas
maneras.
A
pesar
su
prevalencia
y
las
significativas
consecuencias
cotidiana,
adultos
considerablemente
subestimado
subdiagnosticado,
lo
resulta
carga
sustancial
tanto
para
los
individuos
afectados
entorno
familiar
social.
Esta
revisión
exhaustiva
se
propone
explorar
complejidad
del
adultez
aborda
etiología,
definición
presentación
clínica,
factores
riesgo,
comorbilidades
más
frecuentes,
métodos
evaluación
aspectos
neuropsicológicos,
así
enfoques
farmacoterapéuticos
no
tratamiento.
Además,
examinan
implicaciones
diagnóstico
tratamiento,
destacando
importancia
comprensión
integral
esta
condición.
través
este
documento,
Asociación
Argentina
Psiquiatría
Biológica
(AAPB)
aspira
solo
a
recopilar
analizar
sobre
adultos,
sino
también
proporcionar
guía
útil
profesionales
salud
tratan
patología.
Así,
objetivo
final
artículo
es
contribuir
al
desarrollo
estrategias
efectivas
manejo
TDAH,
mejorar
modo
calidad
pacientes.
Life Science Alliance,
Journal Year:
2025,
Volume and Issue:
8(5), P. e202403029 - e202403029
Published: Feb. 25, 2025
Attention-deficit/hyperactivity
disorder
(ADHD)
is
a
heterogeneous
neurodevelopmental
condition
with
high
prevalence
of
co-occurring
conditions,
contributing
to
increased
difficulty
in
long-term
management.
Genome-wide
association
studies
have
identified
variants
shared
between
ADHD
and
psychiatric
disorders;
however,
the
genetic
mechanisms
are
not
fully
understood.
We
integrated
gene
expression
spatial
organization
data
into
two-sample
Mendelian
randomization
study
for
putatively
causal
genes
fetal
adult
cortical
tissues.
four
tissues
(fetal:
ST3GAL3
,
PTPRF
PIDD1
;
adult:
TIE1
).
Protein–protein
interaction
databases
seeded
biological
pathways
linking
these
conditions
(e.g.,
rheumatoid
arthritis)
biomarkers
lymphocyte
counts)
known
be
associated
ADHD,
but
without
previously
shown
relationships.
The
analysis
was
repeated
on
liver
tissue,
where
linked
cholesterol
traits.
This
provides
insight
tissue-dependent
temporal
relationships
traits,
biomarkers.
Importantly,
it
delivers
evidence
interplay
both
studied
unstudied,
ADHD.
European Journal of Preventive Cardiology,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 11, 2025
Abstract
Aims
Attention-deficit/hyperactivity
disorder
(ADHD)
is
increasingly
diagnosed
in
adults
and
associated
with
cardiometabolic
diseases.
Yet,
the
associations
between
ADHD
risk
profile,
participation
non-pharmacological
interventions,
long-term
outcomes
patients
myocardial
infarction
(MI)
remain
unclear.
Methods
results
This
observational
study
involved
from
SWEDEHEART
(the
Swedish
Web-system
for
Enhancement
Development
of
Evidence-based
Care
Heart
Disease
Evaluated
According
to
Recommended
Therapy)
registry,
aged
18–74
years
old,
their
first
acute
MI
2006
2020.
We
assessed
profile
(clinical
parameters,
disease
histories,
behavioural
factors),
engagement
guideline-recommended
recurrent
cardiovascular
events,
mortality.
analysed
(n
=
582)
without
2704).
Most
clinical
parameters
histories
did
not
differ
significantly
groups.
However,
had
higher
risks
smoking
(risk
ratio,
RR
1.53;
95%
confidence
interval
1.36–1.71]
snus
use
(RR
1.65;
1.36–1.99),
were
less
likely
participate
follow-up
evaluations
0.87;
0.79–0.96),
or
stop
after
0.76;
0.63–0.91).
They
a
rate
all-cause
mortality
(hazard
ratio
2.02;
1.05–3.88)
discharge,
but
events.
Conclusion
Adults
present
similar
profiles
poorer
lifestyle
behaviours,
lower
recommended
compared
those
ADHD,
underscoring
need
integrated
cardiology
care
psychiatric
services.
